Immunome Inc. (IMNM): Total Assets
$683.19M
As of 2025-12-31
$565.38M
As of 2026-06-30
+205.1%
3-year compound annual growth
+72.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $683.19M | +184.4% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $240.24M | +61.7% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $148.54M | +517.7% | 2025-03-19, Balance as of period end |
| 2022-12-31 | $24.05M | -58.5% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $57.92M | +30.1% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $44.52M | +779.9% | 2022-03-28, Balance as of period end |
| 2019-12-31 | $5.06M | n/a | 2021-03-25, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Immunome Inc. (IMNM) | 2025-12-31 | $683.19M | +184.4% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $150.83M | +114.5% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $150.93M | +63.8% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $633.16M | -20.7% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $113.51M | -49.8% |
| Adagene Inc. (ADAG) | 2025-12-31 | $78.26M | -12.3% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $56.75M | -43.0% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $160.46M | -27.2% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $49.95M | +12.6% |
Compare IMNM, WHWK, OVID, XENE side by side · Screen every company in Pharmaceutical Preparations ↗